A large meta-analysis found that semaglutide reduced cardiovascular death by 23% and stroke by 32% in people with type 2 diabetes, with even greater benefits for those who also had chronic kidney disease.
32% reduction in stroke riskNonfatal stroke was reduced by nearly a third in type 2 diabetes patients taking semaglutide compared to placebo, based on pooled data from 17 studies.
What the researchers found
Across 17 studies with 40,632 patients, oral semaglutide significantly reduced cardiovascular death by 23% (HR 0.77), major adverse cardiovascular events (MACE) by 18% (HR 0.82), nonfatal heart attacks by 18% (HR 0.82), and nonfatal stroke by 32% (HR 0.68) compared to placebo.
The cardiovascular benefits were most pronounced in patients who also had chronic kidney disease (CKD), with risk reductions of 24–37% compared to 13–35% in those with type 2 diabetes alone or with existing cardiovascular disease. Semaglutide also lowered systolic blood pressure by 8 mmHg and LDL cholesterol by about 13 mg/dL, though it did not significantly affect kidney function markers like eGFR or UACR.
Why it matters
Heart disease is the leading cause of death in people with type 2 diabetes, and the risk is even higher for those who also have kidney disease. This meta-analysis provides the strongest evidence to date that semaglutide not only helps with blood sugar control but also substantially reduces the risk of heart attacks, strokes, and cardiovascular death — particularly in the highest-risk patients with co-existing kidney disease. This positions semaglutide as a multi-benefit treatment rather than just a diabetes drug.
How the study worked
The researchers conducted a systematic review and meta-analysis, searching four major medical databases (PubMed, Embase, Cochrane, and Web of Science) for studies published through September 2025. They included both randomized controlled trials and observational studies that compared oral semaglutide to placebo in people with type 2 diabetes. Data from 17 studies were combined using hazard ratios and mean differences with 95% confidence intervals.
What this study cannot tell us
The analysis combined both randomized controlled trials and observational studies, which may introduce bias. The study focused on oral semaglutide versus placebo, so results may not directly apply to injectable forms. Despite the large total sample size, the CKD subgroup analyses had fewer patients and should be interpreted with some caution. The analysis also could not determine the specific biological mechanisms behind the enhanced benefits seen in kidney disease patients.
How to read the evidence
This is a systematic review and meta-analysis of 17 studies including over 40,000 patients, representing a high level of evidence. The inclusion of both randomized trials and observational data strengthens the real-world applicability but slightly tempers the certainty compared to a meta-analysis of only RCTs.
When this study was published
Published in 2025 with data searched through September 2025, this is a very recent and up-to-date synthesis of the available evidence on semaglutide's cardiovascular effects.
The bigger picture
GLP-1 receptor agonists like semaglutide have rapidly moved beyond their original role as diabetes medications. This meta-analysis reinforces the growing evidence that these peptide-based therapies offer cardiovascular protection that goes well beyond blood sugar management. The finding that benefits are amplified in patients with kidney disease could reshape treatment guidelines for this particularly vulnerable population, potentially making semaglutide a first-line choice for cardiovascular risk reduction in high-risk diabetic patients.
Questions still open
- What are the specific mechanisms by which semaglutide provides greater cardiovascular benefit in patients with chronic kidney disease compared to those without?
- Would injectable semaglutide show similar or greater cardiovascular protection patterns in CKD subgroups?
- Could these findings support using semaglutide for cardiovascular protection even in non-diabetic patients with kidney disease?
Common questions
How much does semaglutide reduce the risk of heart-related events in people with type 2 diabetes?
Why do people with kidney disease see greater heart benefits from semaglutide?
Read the original research
Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease.
European journal of medical research, 30(1), 1059
Citation
Yao, Yanni; Liu, Nairong; Chen, Siyan; Sun, Meng; Guo, Yanjie. (2025). Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease.. European journal of medical research, 30(1), 1059. https://doi.org/10.1186/s40001-025-03241-8